Gene Fusion Testing Market

Q: How big was the global gene fusion testing market in 2024?

It was valued at US$ 0.7 Bn in 2024 Read More

Q: What is the projected size of the gene fusion testing market by 2035?

It is projected to cross US$ 2.5 Bn by the end of 2035 Read More

Gene Fusion Testing Market (Category: Research and Diagnostic; Technology: Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Polymerase Chain Reaction (PCR) and Immunohistochemistry (IHC)) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025–2035

Gene Fusion Testing Market Outlook 2035

The global gene fusion testing market size was valued at US$ 0.7 billion in 2024 and is projected to reach US $ 2.5 billion by 2035, expanding at a CAGR of 12.1% from 2025 to 2035. The market growth is driven by increasing incidence of cancer and rising demand for personalized medicine.

Market Size & Highlights

The Gene fusion testing market reached US$ 0.7 Billion in 2024.
The market is expected to climb to US$ 2.5 Billion by 2035.
The gene fusion testing industry is anticipated to expand at a CAGR of 12.1% from 2025 to 2035.
Top companies in the market include Amoy Diagnostics Co., Ltd., ArcherDX (Integrated DNA Technologies, Inc.), Biocartis, Biocare Medical, LLC, etc.
North America dominated the market in 2024, holding the largest revenue share of 38.3%.
By technology, the next-generation sequencing (NGS) segment held the major market share of 42.1% in 2024.

Gene Fusion Testing Market By Revenue

Analysts’ Viewpoint

The gene fusion testing market is set to experience substantial expansion over the next few years, largely due to the continuous upgradations in genomic technologies and increased involvement of gene fusion in different cancers. Gene fusion events are pivotal in cancer diagnostics and targeted therapies, which are generally used in cancer types like lung cancer, leukemia, and sarcomas.

In addition, the rising incidences of cancer and the demand for personalized treatment options are the main factors that contribute to the market growth. The use of innovative technologies like next-generation sequencing (NGS) and real-time PCR has greatly increased the sensitivity and specificity of gene fusion detection.

Gene Fusion Testing Market Introduction

Gene fusion testing is a major source of information used by oncologists to know what gene fusions are. They are the sequences where two genes combine to form a new one. These fusions, which have been identified in lung cancer, breast cancer, and blood cancers mostly, are usually at the forefront of cancer biomarkers.

In general, gene fusion detection leverages molecular features through instruments such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR) to precisely identify fusion genes and promote the use of personalized medicine, which allows clinicians to decide on the best therapies suitable for the specific genetic changes that take place in a patient’s tumor.

The utility of gene fusion testing in the determination of the most appropriate therapeutics, in the tracking of cancer development, and in the prediction of cancer patient survivability, is growing in parallel with the awareness of cancer genomics. Educational and technological enhancement in gene fusion detection will, thus, lead to quick integration of gene fusion testing into daily clinical routine and result in the precision therapy of cancer being further refined.

Attribute	Detail
Market Drivers	Increasing Incidence of Cancer Rising Demand for Personalized Medicine Supportive Regulatory Framework and Reimbursement Policies

Increasing Incidence of Cancer Expected to Drive Gene Fusion Testing Market Size

The rising number of cancer cases is one of the main reasons leading to the growth of the gene fusion testing market profoundly impacting the demand for advanced diagnostic tools. With cancer rates going up worldwide, which is caused by an aging population, lifestyle, and environmental factors, the requirement for accurate and effective diagnostic methods becomes less dispensable. Gene fusions are the main culprits in the development of cancers of the blood, non-small cell lung cancer, and prostate cancer. Therefore, their detection is the first step for the right diagnosis and treatment.

To coordinate well, doctors are looking to find gene fusions as the key for making therapy that targets these molecular abnormalities. The increasing number of cancer cases has led to research on the genetic composition of the tumors as a result of which there is now a greater emphasis on precision oncology. Therefore, the demand for gene fusion testing is set to increase as it is the main source of information for making treatment decisions and enhancing patient outcomes.

In addition, thanks to the technology upgrades that lead to more rapid and precise testing. Healthcare systems are getting more inclined to these diagnostics methods. As the significance of gene fusions in cancer is getting more comprehendible, the gene fusion testing market will be very vibrant and that will be an indication of the pressing need for solutions in cancer care.

Rising Demand for Personalized Medicine Anticipated to Boost Gene Fusion Testing Market Expansion

The increasing need for personalized medicine is a major factor that drives the gene fusion testing market and goes hand in hand with the shift toward more tailored therapeutic approaches in oncology.

By finding out the gene fusions that may cause the particular cancers, doctors can give treatments that are more effective and have fewer side-effects in comparison with the traditional chemotherapy. This targeted approach not only improves the treatment outcomes but also the risk of side-effects being caused by the treatment is lowered. Moreover, innovations in genomic technologies have eased gene fusion testing procedures, allowing its wide application in clinical settings.

The demand for precise and trustworthy gene fusion testing is sharply increasing, as the benefits of personalized therapies become evident to all the stakeholders - patients, healthcare professionals, and pharmaceutical companies. This trend is being supported further by the research and development activities in precision oncology. Thus the gene fusion testing market is poised for immense expansion as it becomes indispensable in the treatment of cancer.

Next-Generation Sequencing (NGS) Technology Segment Driving Gene Fusion Testing Market Growth

Gene Fusion Testing Market By Technology

NGS is a major market driver for gene fusion testing market with its unmatched ability to simultaneously analyze multiple genes with high accuracy and efficiency,

NGS enables comprehensive genomic profiling and thus the detection of diverse gene fusions that may be the central of cancer biology. In contrast to traditional methods that generally single out genes or mutations, NGS can identify a wide array of genetic changes, thus giving a more complete picture of the molecular makeup of the tumor.

Furthermore, the affordability and scalability of NGS have paved the way for its acceptance in many clinical laboratories. Sequencing, in general, is made more accessible to healthcare providers as the costs continue to drop, thus routine cancer diagnostics can be performed by them. This instrument of care speeds up testing.

In addition, NGS, combined with bioinformatics tools, provides for more complex data handling and interpretation, thus personalized medicine benefits from it even more. Consequently, the increasing dependency on NGS for gene fusion detection not only facilitates market expansion at a rapid pace but also patient outcomes improvement by recommending the targeted therapies based on genetic alterations of the tumor.

Regional Outlook of Gene Fusion Testing Market

Gene Fusion Testing Market By Region

Attribute	Detail
Leading Region	North America

North America leads the gene fusion testing market, holding the largest revenue share of 38.3%, as an outcome of a combination of an advanced healthcare system, growing focus on personalized medicine, and high levels of research and development. This region is home to many top-tier pharmaceutical and biotech companies that are heavily investing in genomic research and the creation of innovative diagnostic tools.

Furthermore, rising incidences of cancer in North America have led to an increased demand for effective diagnostic solutions. Healthcare providers are realizing the importance of gene fusion testing in personalizing treatment plans, hence its adoption is spreading fast.

Also, the population in North America is more informed about genetic testing and personalized medicine, which is amongst the factors contributing to the demand for such services.

Analysis of Key Players in Gene Fusion Testing Market

Amoy Diagnostics Co., Ltd., ArcherDX (Integrated DNA Technologies, Inc.), Biocartis, Biocare Medical, LLC, F. Hoffmann-La Roche Ltd., Guardant Health, Inc, Illumina, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc are the key players governing the global gene fusion testing market.

Each of these players has been profiled in the gene fusion testing market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

In July 2025, Thermo Fisher Scientific received FDA’s approval for its Oncomine Dx Express Test (on the Ion Torrent Genexus Dx) as a companion diagnostic and tumor-profiling NGS assay, a milestone that also impacts fusion detection workflows.
In October 2025, Gene Solutions and AMPATH launched a new advanced genomics laboratory in Hyderabad (India) to expand access to NGS-based testing (including oncology/precision medicine, which implicates fusion testing) in the region.
In September 2024, NeoGenomics, Inc. announced real-world data to be presented at ESMO 2024 showing that testing for 19 drug-targetable gene fusions via NGS identified up to four times more patients eligible for matched therapies compared to tests focusing only on NTRK fusions or using IHC.

Gene Fusion Testing Market Snapshot

Attribute	Detail
Size in 2024	US$ 0.7 Bn
Forecast Value in 2035	More than US$ 2.5 Bn
CAGR	12.1%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	By Category Research Diagnostic By Technology Next-Generation Sequencing (NGS) Fluorescence In-Situ Hybridization (FISH) Polymerase Chain Reaction (PCR) Immunohistochemistry (IHC) By Indication Solid Tumors Hematological Malignancies By End-user Pharmaceutical and Biotechnology Companies Hospitals and Diagnostic Laboratories Academic and Research Centers
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China India Japan South Korea Australia ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Amoy Diagnostics Co., Ltd. ArcherDX (Integrated DNA Technologies, Inc.) Biocartis Biocare Medical, LLC F. Hoffmann-La Roche Ltd. Guardant Health, Inc Illumina, Inc. Myriad Genetics, Inc. Natera, Inc. NeoGenomics, Inc. QIAGEN N.V. Thermo Fisher Scientific Inc Other Prominent Players
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global gene fusion testing market in 2024?

It was valued at US$ 0.7 Bn in 2024

What is the projected size of the gene fusion testing market by 2035?

It is projected to cross US$ 2.5 Bn by the end of 2035

What are the factors driving the gene fusion testing market?

Increasing incidence of cancer and rising demand for personalized medicine

What is the gene fusion testing industry expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 12.1% from 2025 to 2035

Which region is expected to dominate the gene fusion testing market during the forecast period?

North America is expected to account for the largest share from 2025 to 2035

Who are the prominent gene fusion testing providers?

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Gene Fusion Testing Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Gene Fusion Testing Market Analysis and Forecast, 2020-2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Key Industry Events
- Impact Analysis
- PESTEL Analysis
- PORTER’s Five Forces Analysis
- Regulatory Scenario by Key Countries/Regions
- Healthcare Expenditure by Country
- Fund Raise/Investment Scenario
- Potential Investment Risks
- Ecosystem Analysis
Global Gene Fusion Testing Market Analysis and Forecast, by Category
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Category, 2020-2035
  - Research
  - Diagnostic
- Market Attractiveness Analysis, by Category
Global Gene Fusion Testing Market Analysis and Forecast, by Technology
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Technology, 2020-2035
  - Next-Generation Sequencing (NGS)
  - Fluorescence In-Situ Hybridization (FISH)
  - Polymerase Chain Reaction (PCR)
  - Immunohistochemistry (IHC)
- Market Attractiveness Analysis, by Technology
Global Gene Fusion Testing Market Analysis and Forecasts, by Indication
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Indication, 2020-2035
  - Solid Tumors
  - Hematological Malignancies
- Market Attractiveness Analysis, by Indication
Global Gene Fusion Testing Market Analysis and Forecast, by Application
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Application, 2020-2035
  - Pharmaceutical and Biotechnology Companies
  - Hospitals and Diagnostic Laboratories
  - Academic and Research Centers
- Market Attractiveness Analysis, by Application
Global Gene Fusion Testing Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020-2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness By Country/Region
North America Gene Fusion Testing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Category, 2020-2035
  - Research
  - Diagnostic
- Market Value Forecast, by Technology, 2020-2035
  - Next-Generation Sequencing (NGS)
  - Fluorescence In-Situ Hybridization (FISH)
  - Polymerase Chain Reaction (PCR)
  - Immunohistochemistry (IHC)
- Market Value Forecast, by Indication, 2020-2035
  - Solid Tumors
  - Hematological Malignancies
- Market Value Forecast, by Application, 2020-2035
  - Pharmaceutical and Biotechnology Companies
  - Hospitals and Diagnostic Laboratories
  - Academic and Research Centers
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Category
  - By Technology
  - By Indication
  - By Application
  - By Country/Sub-region
Europe Gene Fusion Testing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Category, 2020-2035
  - Research
  - Diagnostic
- Market Value Forecast, by Technology, 2020-2035
  - Next-Generation Sequencing (NGS)
  - Fluorescence In-Situ Hybridization (FISH)
  - Polymerase Chain Reaction (PCR)
  - Immunohistochemistry (IHC)
- Market Value Forecast, by Indication, 2020-2035
  - Solid Tumors
  - Hematological Malignancies
- Market Value Forecast, by Application, 2020-2035
  - Pharmaceutical and Biotechnology Companies
  - Hospitals and Diagnostic Laboratories
  - Academic and Research Centers
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Germany
  - UK
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Category
  - By Technology
  - By Indication
  - By Application
  - By Country/Sub-region
Asia Pacific Gene Fusion Testing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Category, 2020-2035
  - Research
  - Diagnostic
- Market Value Forecast, by Technology, 2020-2035
  - Next-Generation Sequencing (NGS)
  - Fluorescence In-Situ Hybridization (FISH)
  - Polymerase Chain Reaction (PCR)
  - Immunohistochemistry (IHC)
- Market Value Forecast, by Indication, 2020-2035
  - Solid Tumors
  - Hematological Malignancies
- Market Value Forecast, by Application, 2020-2035
  - Pharmaceutical and Biotechnology Companies
  - Hospitals and Diagnostic Laboratories
  - Academic and Research Centers
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - China
  - India
  - Japan
  - South Korea
  - ASEAN
  - Australia
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Category
  - By Technology
  - By Indication
  - By Application
  - By Country/Sub-region
Latin America Gene Fusion Testing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Category, 2020-2035
  - Research
  - Diagnostic
- Market Value Forecast, by Technology, 2020-2035
  - Next-Generation Sequencing (NGS)
  - Fluorescence In-Situ Hybridization (FISH)
  - Polymerase Chain Reaction (PCR)
  - Immunohistochemistry (IHC)
- Market Value Forecast, by Indication, 2020-2035
  - Solid Tumors
  - Hematological Malignancies
- Market Value Forecast, by Application, 2020-2035
  - Pharmaceutical and Biotechnology Companies
  - Hospitals and Diagnostic Laboratories
  - Academic and Research Centers
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Category
  - By Technology
  - By Indication
  - By Application
  - By Country/Sub-region
Middle East & Africa Gene Fusion Testing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Category, 2020-2035
  - Research
  - Diagnostic
- Market Value Forecast, by Technology, 2020-2035
  - Next-Generation Sequencing (NGS)
  - Fluorescence In-Situ Hybridization (FISH)
  - Polymerase Chain Reaction (PCR)
  - Immunohistochemistry (IHC)
- Market Value Forecast, by Indication, 2020-2035
  - Solid Tumors
  - Hematological Malignancies
- Market Value Forecast, by Application, 2020-2035
  - Pharmaceutical and Biotechnology Companies
  - Hospitals and Diagnostic Laboratories
  - Academic and Research Centers
- Market Value Forecast, by Country/Sub-region, 2020-2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Category
  - By Technology
  - By Indication
  - By Application
  - By Country/Sub-region
Competition Landscape
- Market Player - Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - Amoy Diagnostics Co., Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - ArcherDX (Integrated DNA Technologies, Inc.)
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Biocartis
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Biocare Medical, LLC
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - F. Hoffmann-La Roche Ltd.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Guardant Health, Inc
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Illumina, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Myriad Genetics, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Natera, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - NeoGenomics, Inc.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - QIAGEN N.V.
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Thermo Fisher Scientific Inc
    - Company Overview
    - Financial Overview
    - Product Portfolio
    - Business Strategies
    - Recent Developments
  - Other Prominent Players

List of Tables

Table 01: Global Gene Fusion Testing Market Value (US$ Bn) Forecast, By Category, 2020 to 2035
Table 02: Global Gene Fusion Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 03: Global Gene Fusion Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 04: Global Gene Fusion Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 05: Global Gene Fusion Testing Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 06: North America - Gene Fusion Testing Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 07: North America Gene Fusion Testing Market Value (US$ Bn) Forecast, By Category, 2020 to 2035
Table 08: North America Gene Fusion Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 09: North America Gene Fusion Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 10: North America Gene Fusion Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 11: Europe - Gene Fusion Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 12: Europe Gene Fusion Testing Market Value (US$ Bn) Forecast, By Category, 2020 to 2035
Table 13: Europe Gene Fusion Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 14: Europe Gene Fusion Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 15: Europe Gene Fusion Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 16: Asia Pacific - Gene Fusion Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 17: Asia Pacific Gene Fusion Testing Market Value (US$ Bn) Forecast, By Category, 2020 to 2035
Table 18: Asia Pacific Gene Fusion Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 19: Asia Pacific Gene Fusion Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 20: Asia Pacific Gene Fusion Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 21: Latin America - Gene Fusion Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 22: Latin America Gene Fusion Testing Market Value (US$ Bn) Forecast, By Category, 2020 to 2035
Table 23: Latin America Gene Fusion Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 24: Latin America Gene Fusion Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 25: Latin America Gene Fusion Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 26: Middle East & Africa - Gene Fusion Testing Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
Table 27: Middle East & Africa Gene Fusion Testing Market Value (US$ Bn) Forecast, By Category, 2020 to 2035
Table 28: Middle East & Africa Gene Fusion Testing Market Value (US$ Bn) Forecast, By Technology, 2020 to 2035
Table 29: Middle East & Africa Gene Fusion Testing Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 30: Middle East & Africa Gene Fusion Testing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Gene Fusion Testing Market Value Share Analysis, By Category, 2024 and 2035
Figure 02: Global Gene Fusion Testing Market Attractiveness Analysis, By Category, 2025 to 2035
Figure 03: Global Gene Fusion Testing Market Revenue (US$ Bn), by Research, 2020 to 2035
Figure 04: Global Gene Fusion Testing Market Revenue (US$ Bn), by Diagnostic, 2020 to 2035
Figure 05: Global Gene Fusion Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 06: Global Gene Fusion Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 07: Global Gene Fusion Testing Market Revenue (US$ Bn), by Next-Generation Sequencing (NGS), 2020 to 2035
Figure 08: Global Gene Fusion Testing Market Revenue (US$ Bn), by Fluorescence In-Situ Hybridization (FISH), 2020 to 2035
Figure 09: Global Gene Fusion Testing Market Revenue (US$ Bn), by Polymerase Chain Reaction (PCR), 2020 to 2035
Figure 10: Global Gene Fusion Testing Market Revenue (US$ Bn), by Immunohistochemistry (IHC), 2020 to 2035
Figure 11: Global Gene Fusion Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 12: Global Gene Fusion Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 13: Global Gene Fusion Testing Market Revenue (US$ Bn), by Solid Tumors, 2020 to 2035
Figure 14: Global Gene Fusion Testing Market Revenue (US$ Bn), by Hematological Malignancies, 2020 to 2035
Figure 15: Global Gene Fusion Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 16: Global Gene Fusion Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 17: Global Gene Fusion Testing Market Revenue (US$ Bn), by Pharmaceutical and Biotechnology Companies, 2020 to 2035
Figure 18: Global Gene Fusion Testing Market Revenue (US$ Bn), by Hospitals and Diagnostic Laboratories, 2020 to 2035
Figure 19: Global Gene Fusion Testing Market Revenue (US$ Bn), by Academic and Research Centers, 2020 to 2035
Figure 20: Global Gene Fusion Testing Market Value Share Analysis, By Region, 2024 and 2035
Figure 21: Global Gene Fusion Testing Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 22: North America Gene Fusion Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 23: North America Gene Fusion Testing Market Value Share Analysis, by Country, 2024 and 2035
Figure 24: North America Gene Fusion Testing Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 25: North America Gene Fusion Testing Market Value Share Analysis, By Category, 2024 and 2035
Figure 26: North America Gene Fusion Testing Market Attractiveness Analysis, By Category, 2025 to 2035
Figure 27: North America Gene Fusion Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 28: North America Gene Fusion Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 29: North America Gene Fusion Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 30: North America Gene Fusion Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 31: North America Gene Fusion Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 32: North America Gene Fusion Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 33: Europe Gene Fusion Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 34: Europe Gene Fusion Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 35: Europe Gene Fusion Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 36: Europe Gene Fusion Testing Market Value Share Analysis, By Category, 2024 and 2035
Figure 37: Europe Gene Fusion Testing Market Attractiveness Analysis, By Category, 2025 to 2035
Figure 38: Europe Gene Fusion Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 39: Europe Gene Fusion Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 40: Europe Gene Fusion Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 41: Europe Gene Fusion Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 42: Europe Gene Fusion Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 43: Europe Gene Fusion Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 44: Asia Pacific Gene Fusion Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 45: Asia Pacific Gene Fusion Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 46: Asia Pacific Gene Fusion Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 47: Asia Pacific Gene Fusion Testing Market Value Share Analysis, By Category, 2024 and 2035
Figure 48: Asia Pacific Gene Fusion Testing Market Attractiveness Analysis, By Category, 2025 to 2035
Figure 49: Asia Pacific Gene Fusion Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 50: Asia Pacific Gene Fusion Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 51: Asia Pacific Gene Fusion Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 52: Asia Pacific Gene Fusion Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 53: Asia Pacific Gene Fusion Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 54: Asia Pacific Gene Fusion Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 55: Latin America Gene Fusion Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 56: Latin America Gene Fusion Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 57: Latin America Gene Fusion Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 58: Latin America Gene Fusion Testing Market Value Share Analysis, By Category, 2024 and 2035
Figure 59: Latin America Gene Fusion Testing Market Attractiveness Analysis, By Category, 2025 to 2035
Figure 60: Latin America Gene Fusion Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 61: Latin America Gene Fusion Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 62: Latin America Gene Fusion Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 63: Latin America Gene Fusion Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 64: Latin America Gene Fusion Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 65: Latin America Gene Fusion Testing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 66: Middle East & Africa Gene Fusion Testing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 67: Middle East & Africa Gene Fusion Testing Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 68: Middle East & Africa Gene Fusion Testing Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 69: Middle East & Africa Gene Fusion Testing Market Value Share Analysis, By Category, 2024 and 2035
Figure 70: Middle East & Africa Gene Fusion Testing Market Attractiveness Analysis, By Category, 2025 to 2035
Figure 71: Middle East & Africa Gene Fusion Testing Market Value Share Analysis, By Technology, 2024 and 2035
Figure 72: Middle East & Africa Gene Fusion Testing Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 73: Middle East & Africa Gene Fusion Testing Market Value Share Analysis, By Indication, 2024 and 2035
Figure 74: Middle East & Africa Gene Fusion Testing Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 75: Middle East & Africa Gene Fusion Testing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 76: Middle East & Africa Gene Fusion Testing Market Attractiveness Analysis, By End-user, 2025 to 2035